Purpose: To explore the correlations between treatment modalities and selected disease parameters with outcome in febrile infection-related epilepsy syndrome (FIRES), a catastrophic epileptic encephalopathy with a yet undefined etiology.
Methods: We conducted a retrospective multicenter study on children who had been included in eight studies published between November 2001 and July 2010. Additional data were retrieved from six of the eight participating centers.
Key Findings: The 77 enrolled patients presented with prolonged refractory status epilepticus. A preceding febrile infection had been reported in 96% of them. Treatment modalities included antiepileptic drugs (a median of six), intravenous immunoglobulin (IVIG, 30 patients), steroids (29 patients), burst-suppression coma (BSC, 46 patients), and other less conventional agents. There was no evidence of efficacy for those treatment modalities except for IVIG (two patients), a ketogenic diet (one patient), and a prolonged cycle of barbiturate anesthesia coma (one patient). Nine patients (11.7%) died during the acute phase of FIRES. Only 12 of the 68 surviving patients (18%) retained normal cognitive level, but most of them had learning disabilities. Sixty-three patients (93%) had refractory epilepsy at follow-up. Cognitive levels at follow-up were significantly associated with duration of BSC (p = 0.005) and younger age at FIRES onset (p = 0.02).
Significance: The outcome of FIRES is poor. No therapeutic agent was efficacious in shortening the acute phase, with the possible exception of a ketogenic diet. Treatment by inducing a prolonged BSC was associated with a worse cognitive outcome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1528-1167.2011.03250.x | DOI Listing |
Am Soc Clin Oncol Educ Book
January 2025
City of Hope National Medical Center, Duarte, CA.
Data have matured to support incorporation of integrative oncology modalities into comprehensive cancer care. Clinical practice guidelines have recently been published by ASCO for diet and exercise (2022) and use of cannabinoids and cannabis (2024) and jointly by ASCO and the Society for Integrative Oncology (SIO) for application of integrative approaches in the management of pain (2022), anxiety and depression (2023), and fatigue (2024) among adults with cancer. Following the ASCO-SIO guidelines, clinicians should recommend mindfulness-based interventions (MBIs) to patients with symptoms of anxiety or depression and MBIs and exercise for management of fatigue during or after completion of cancer treatment.
View Article and Find Full Text PDFBlood
January 2025
IDIBAPS, Barcelona, Spain.
Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern as compared to normal B cells. Here, we explored whether the level of chromatin activation is related to the clinical behavior of CLL. We identified that in some regulatory regions, increased de novo chromatin activation is linked to clinical progression whereas, in other regions, it is associated with an indolent course.
View Article and Find Full Text PDFMinerva Dent Oral Sci
January 2025
RAK College of Dental Sciences, Department of Prosthodontics, RAK Medical and Health Sciences University, Ras Al-Khaimah, United Arab Emirates.
Introduction: The aim of this study was to evaluate the long-term treatment outcomes of basal implants in patients with severely resorbed ridges, including the survival and success rates, patient complaints, satisfaction, and Quality of Life.
Evidence Acquisition: An extensive electronic search was conducted on the search engines: PubMed, Web of Science, and Google Scholar using Boolean Operators (AND, OR, NOT) and the key words (basal implants, Corticobasal implants, Strategic Implants, severely resorbed ridge, severely atrophic ridge, treatment outcome, patient satisfaction) within the last 10 years.
Evidence Synthesis: A total of 21 articles were found, encompassing 9732 basal implants placed in 1219 patients.
Cancer J
January 2025
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
There is major interest in deintensifying therapy for isocitrate dehydrogenase-mutant low-grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors. These efforts need head-to-head comparisons with proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic clinical risk factors.
View Article and Find Full Text PDFPhotochem Photobiol Sci
January 2025
Nanosensors Laboratory, Research & Development Institute, University of Vale do Paraíba, Av. Shishima Hifumi, 2911, Urbanova, São José dos Campos, São Paulo, Brazil.
Breast cancer is the deadliest cancer among women and its treatment using traditional methods leads the patient to experience adverse effects. However, photodynamic therapy (PDT) is a non-invasive therapy modality that works through a photosensitizing agent, which treating activated by a suitable light source, releases reactive oxygen species capable of treating cancer. Furthermore, recent research indicates that combining PDT and nanoparticles can enhance therapeutic effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!